Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma.

IF 1.4 Q4 ONCOLOGY

Molecular and clinical oncology Pub Date : 2023-09-01 DOI:10.3892/mco.2023.2669

Aikaterini Aravantinou-Fatorou, Vasiliki Epameinondas Georgakopoulou, Nikolaos Mathioudakis, Petros Papalexis, Kyriakos Tarantinos, Ilias Trakas, Nikolaos Trakas, Demetrios A Spandidos, George Fotakopoulos

{"title":"Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma.","authors":"Aikaterini Aravantinou-Fatorou, Vasiliki Epameinondas Georgakopoulou, Nikolaos Mathioudakis, Petros Papalexis, Kyriakos Tarantinos, Ilias Trakas, Nikolaos Trakas, Demetrios A Spandidos, George Fotakopoulos","doi":"10.3892/mco.2023.2669","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma multiforme (GBM) is the most frequent and malignant primary central nervous system tumor in adults. The gold-standard management of GBM includes post-operative radiotherapy (RT) with concurrent and secondary temozolomide (TMZ) treatment. The present meta-analysis study examined the efficacy of the early administration of bevacizumab prior to standard RT plus TMZ in managing patients with GBM and unfavorable prognostic factors. Between 1983 and 2020, the present study looked for comparative articles involving standard RT plus TMZ and RT/TMZ combined with bevacizumab treatment in patients with GBM. The primary outcomes involved in this study include progression-free survival and overall survival. The present study suggested that bevacizumab administration plus standard RT/TMZ (BEV group) treatment was associated with increased survival of patients with GBM compared with those treated with standard RT/TMZ (CG/Control group) treatment only.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/ee/mco-19-03-02669.PMC10442729.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mco.2023.2669","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Glioblastoma multiforme (GBM) is the most frequent and malignant primary central nervous system tumor in adults. The gold-standard management of GBM includes post-operative radiotherapy (RT) with concurrent and secondary temozolomide (TMZ) treatment. The present meta-analysis study examined the efficacy of the early administration of bevacizumab prior to standard RT plus TMZ in managing patients with GBM and unfavorable prognostic factors. Between 1983 and 2020, the present study looked for comparative articles involving standard RT plus TMZ and RT/TMZ combined with bevacizumab treatment in patients with GBM. The primary outcomes involved in this study include progression-free survival and overall survival. The present study suggested that bevacizumab administration plus standard RT/TMZ (BEV group) treatment was associated with increased survival of patients with GBM compared with those treated with standard RT/TMZ (CG/Control group) treatment only.

Abstract Image

查看原文本刊更多论文

胶质母细胞瘤患者贝伐单抗和/或替莫唑胺/放射手术治疗后结果的比较

多形性胶质母细胞瘤(GBM)是成人最常见的原发性中枢神经系统恶性肿瘤。GBM的金标准管理包括术后放疗(RT)和并发和二次替莫唑胺(TMZ)治疗。目前的荟萃分析研究检查了在标准RT + TMZ治疗GBM和不良预后因素患者之前早期给予贝伐单抗的疗效。在1983年至2020年期间，本研究寻找了涉及标准RT + TMZ和RT/TMZ联合贝伐单抗治疗GBM患者的比较文章。本研究涉及的主要结局包括无进展生存期和总生存期。目前的研究表明，与仅接受标准RT/TMZ (CG/对照组)治疗的患者相比，贝伐单抗加标准RT/TMZ (BEV组)治疗与GBM患者的生存率增加相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and clinical oncology ONCOLOGY-

CiteScore

2.80

自引率

0.00%

发文量

108